Current Report Filing (8-k)
February 02 2022 - 8:07AM
Edgar (US Regulatory)
0001314052
false
0001314052
2022-02-02
2022-02-02
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): February 2, 2022
ANAVEX
LIFE SCIENCES CORP.
(Exact
name of registrant as specified in its charter)
Nevada
|
001-37606
|
98-0608404
|
(State or other jurisdiction
|
(Commission
|
(IRS Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
630
5th Avenue, 20th Floor
New
York, NY 10111
(Address
of principal executive offices) (Zip Code)
|
1-844-689-3939
(Registrant’s
telephone number, including area code)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
☐
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered
pursuant to Section 12(b) of the Act:
Title
of Each Class
|
|
Trading
Symbol
|
|
Name
of Each Exchange on Which Registered
|
Common
Stock, par value $0.001 per share
|
|
AVXL
|
|
The
Nasdaq Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01
|
Regulation FD Disclosure.
|
On February 2, 2022, Anavex Life
Sciences Corp., a Nevada corporation (the “Company”) made available a data presentation (the “Data Presentation”),
which was delivered by the Company’s Chief Executive Officer and President, Christopher Missling, PhD and the Company’s Chief
Medical Officer, Ed Hammond, MD, PhD. via webcast. The Data Presentation is attached to this Current Report on Form 8-K as Exhibit 99.1
and incorporated herein by reference.
The information included in this
Item 7.01 and in Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or otherwise subject to the liabilities of that Section or incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such
a filing.
The Company undertakes no duty
or obligation to update or revise information included in this Report or the Exhibit.
Item 9.01
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ANAVEX LIFE SCIENCES CORP.
|
|
|
|
By:
|
/s/Christopher Missling
|
|
|
Name: Christopher Missling, PhD
Title: Chief Executive Officer
|
Date: February 2, 2022
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Sep 2023 to Sep 2024